Sugi Predict

Sugi Predict / Compounds / SCHEMBL297006

SCHEMBL297006

SCHEMBL297006

CN(Cc1cccc(Cl)c1)C(=O)C(F)(CCN1CCC(NS(C)(=O)=O)CC1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TACR3 P29371 4/20 0.49
▸ TACR2 P21452 3/20 0.49
▸ TACR1 P25103 3/20 0.49
▸ RIPK1 Q13546 1/20 0.39
▸ SIGMAR1 Q99720 5/20 0.39
▸ UBE2M P61081 1/20 0.39
▸ DCUN1D1 Q96GG9 1/20 0.39
▸ CARM1 Q86X55 1/20 0.37
▸ PRMT6 Q96LA8 1/20 0.37
▸ CCR5 P51681 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ APAF1 O14727 1/20 0.36
▸ UBE2N P61088 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922238 0.91 TACR2 (0.51) TACR3TACR2TACR1SIGMAR1CCR5
SCHEMBL299938 0.90 TACR3 (0.57) TACR3TACR2TACR1RIPK1SIGMAR1
SCHEMBL297276 0.90 TACR3 (0.51) TACR3TACR2TACR1SIGMAR1CCR5
SCHEMBL296183 0.89 TACR2 (0.56) TACR3TACR2TACR1CCR5KMT2A
SCHEMBL296897 0.89 TACR2 (0.48) TACR3TACR2TACR1SIGMAR1UBE2M
SCHEMBL297869 0.89 TACR3 (0.64) TACR3TACR2TACR1UBE2MDCUN1D1
SCHEMBL297435 0.87 TACR3 (0.58) TACR3TACR2TACR1SIGMAR1DCUN1D1
SCHEMBL297619 0.87 TACR3 (0.56) TACR3TACR2TACR1CCR5
SCHEMBL296317 0.85 TACR3 (0.58) TACR3TACR2TACR1SIGMAR1UBE2M
SCHEMBL296043 0.84 TACR3 (0.51) TACR3TACR2TACR1SIGMAR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200982-B1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-03-14 — — EP disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 — — US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 — — US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 — — US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 — — US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 — — US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 TACR3 95/4885TACR2 21/4885TACR1 26/4885
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 TACR3 95/4885TACR2 21/4885TACR1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.